Global Malignant Pleural Mesothelioma (MPM) Pipeline Insights Report 2020: MTG201, YS110, Poly-ICLC (Hiltonol) Vaccine, rAd-IFN, Nivolumab and ipilimumab, ONCOS-102 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Malignant Pleural Mesothelioma (MPM) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Malignant Pleural Mesothelioma (MPM) - Pipeline Insight, 2020," report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Malignant Pleural Mesothelioma pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Treatment

Although there is no cure for mesothelioma, some patients live much longer with treatments. Combining several treatments, such as surgery, chemotherapy and radiation therapy, has helped some people live for years. Surgery is controversial and limited to patients with early stage disease and good functional status. Palliative care and symptom management are essential and the control of pleural effusions is an important factor. Clinical trials offer access to new treatments such as immunotherapy.

Malignant Pleural Mesothelioma Emerging Drugs Chapters

This segment of the Malignant Pleural Mesothelioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Malignant Pleural Mesothelioma Emerging Drugs

MTG201: Momotaro-Gene Inc.

MTG201 is a novel investigational gene therapy with unique dual mechanisms of action capable of addressing a range of cancers. The drug candidate leverages the company's proprietary adenoviral vector technology platform to deliver the Reduced Expression in Immortalized Cells/Dickkopf-3 gene (REIC/Dkk-3 gene) into cancer cells, where the expression of the gene has been shown to be markedly downregulated. The resulting increase in REIC/Dkk-3 gene expression in cancer cells triggers immunogenic cell death selectively in cancer cells.

At the same time, increased expression of REIC/Dkk-3 gene in normal cell components in tumor tissue promotes anti-tumor immunity by activating dendritic cells and natural killer (NK) cells while suppressing immune suppressive regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSC). Based on these novel dual mechanisms, MTG201 is believed to be well positioned to work synergistically with checkpoint inhibitors such as nivolumab.

YS110: Kissei Pharmaceutical Co., Ltd.

YS110 is a humanized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the extracellular domain of dipeptidyl peptidase 4 (CD26; DPP4; DPP IV), with potential antineoplastic activity. Upon administration of anti-CD26 monoclonal antibody YS110, this antibody targets and binds to CD26 expressed on tumor cells. This inhibits CD26 activity and causes internalization of CD26-YS110. This leads to cell cycle arrest, lysis and inhibition of growth in CD26-positive tumor cells.

YS110 also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CD26-expressing tumor cells. CD26, a 110-kDa, type II transmembrane glycoprotein, is overexpressed in a variety of cancer cell types while absent in normal, healthy cells and plays a key role in tumor cell growth, migration, invasion and survival. It also plays a major role in the regulation of T-cell activity.

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Malignant Pleural Mesothelioma drugs?
• How many Malignant Pleural Mesothelioma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant Pleural Mesothelioma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Malignant Pleural Mesothelioma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Malignant Pleural Mesothelioma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Momotaro-Gene Inc.
• Kissei Pharmaceutical Co., Ltd.
• Oncovir, Inc.
• Trizell Ltd.
• Merck
• Bristol-Myers Squibb
• Theradex
• Targovax Oy
• Hoffmann-La Roche

Key Products

• MTG201
• YS110
• Poly-ICLC (Hiltonol) Vaccine
• rAd-IFN
• Nivolumab and ipilimumab
• ONCOS-102

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ciadkm

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900